Literature DB >> 27186227

Usefulness of anterior uveitis as an additional tool for diagnosing incomplete Kawasaki disease.

Kyu Jin Lee1, Hyo Jin Kim1, Min Jae Kim1, Ji Hong Yoon1, Eun Jung Lee1, Jae Young Lee1, Jin Hee Oh1, Soon Ju Lee1, Kyung Yil Lee1, Ji Whan Han1.   

Abstract

PURPOSE: There are no specific tests for diagnosing Kawasaki disease (KD). Additional diagnostic criteria are needed to prevent the delayed diagnosis of incomplete Kawasaki disease (IKD). This study compared the frequency of coronary artery lesions (CALs) in IKD patients with and without anterior uveitis (AU) and elucidated whether the finding of AU supported the diagnosis of IKD.
METHODS: This study enrolled patients diagnosed with IKD at The Catholic University of Korea, Uijeongbu St. Mary's Hospital from January 2010 to December 2014. The patients were divided into 2 groups: group 1 included patients with IKD having AU; and group 2 included patients with IKD without AU. We analyzed the demographic and clinical data (age, gender, duration of fever, and the number of diagnostic criteria), laboratory results, and echocardiographic findings.
RESULTS: Of 111 patients with IKD, 41 had uveitis (36.98%, group 1) and 70 did not (63.02%, group 2). Patients in group 1 had received a diagnosis and treatment earlier, and had fewer CALs (3 of 41, 1.7%) than those in group 2 (20 of 70, 28.5%) (P=0.008). All 3 patients with CALs in group 1 had coronary dilatation, while patients with CALs in group 2 had CALs ranging from coronary dilatation to giant aneurysm.
CONCLUSION: The diagnosis of IKD is challenging but can be supported by the presence of features such as AU. Group 1 had a lower risk of coronary artery disease than group 2. Therefore, the presence of AU is helpful in the early diagnosis and treatment of IKD and can be used as an additional diagnostic tool.

Entities:  

Keywords:  Anterior uveitis; Coronary artery; Delayed diagnosis; Kawasaki disease

Year:  2016        PMID: 27186227      PMCID: PMC4865640          DOI: 10.3345/kjp.2016.59.4.174

Source DB:  PubMed          Journal:  Korean J Pediatr        ISSN: 1738-1061


Introduction

Kawasaki disease (KD) is an acute, systemic vasculitis of unknown etiology that occurs predominantly in infants and young children less than 5 years old. It was firstly reported by Kawasaki in 19671), and has subsequently been reported worldwide in children of all races. A delayed diagnosis of KD, especially incomplete Kawasaki disease (IKD)2); which has persistent fever with fewer than four other principal clinical features of KD, can lead to the development of coronary artery lesions (CALs). Recently, the diagnosis of IKD has been increasing, and the reported prevalence was 15% to 36.2% among patients with KD345678), making it difficult for pediatrician to diagnose KD. Therefore, additional clues that are helpful in the diagnosis of IKD are needed for the early detection and treatment of IKD. Suggested clues are erythema and induration of a previous Bacille Calmette-Guerin inoculation site910), anterior uveitis (AU)11), elevated serum levels of alanine aminotransferase (ALT)12), brain natriuretic peptide (BNP)13) and N-terminal pro-BNP1415), hyponatremia16), echocardiographic abnormalities other than CALs17) (pericardial effusion, dysfunction of the left ventricle, mitral regurgitation). AU is a common finding in the early stage of KD, so a slit lamp examination may be a helpful in the early detection of patients with IKD. No study has examined the usefulness of AU for the early recognition and treatment of IKD in Korea. Therefore, we retrospectively investigated the diagnostic value of AU for the early detection of IKD.

Materials and methods

1. Patients

This study enrolled patients diagnosed with KD at The Catholic University of Korea, Uijeongbu St. Mary's Hospital from January 2010 to December 2014. The patients were divided to 2 groups on admission: group 1 presented with sustained fever and two or three principal features of KD with AU; group 2 presented with sustained fever with two or three principal features of KD without AU. We analyzed the following data obtained from a retrospective review of the charts of the enrolled patients with KD during hospital admission leading to the final diagnosis: clinical and demographic data (age, gender, duration of fever, and the number of diagnostic criteria), laboratory values before the administration of intravenous immunoglobulin (IVIG), response to IVIG, and echocardiographic findings. All patients were treated with IVIG (2 g/kg) and aspirin (50 mg/kg) as the first-line treatment. The response to the initial IVIG treatment was considered "refractory"12) if persistent or recrudescent fever was noted at least 36 hours after IVIG administration. Refractory KD was treated using additional IVIG infusions or the second-line therapy, such as systemic corticosteroids or infliximab.

2. Ophthalmologic examination

All patients with IKD underwent ophthalmology consultations to confirm the existence of AU. AU was diagnosed by slit-lamp examination and graded using Standardization of Uveitis Nomenclature (SUN) Grading Scheme for Anterior Chamber Cells and SUN Grading Scheme for Anterior Chamber Flare.

3. Blood tests

The laboratory tests were performed on admission (before the IVIG infusion) and during the course of the disease, including compete blood cell counts, erythrocyte sedimentation rate, C-reactive protein, serum albumin, and serum ALT.

4. Echocardiographic examinations

Two-dimensional echocardiography was performed during hospitalization and follow-up periods at the outpatient clinic (1 month and 1 year after discharge). The internal diameters of left main, left anterior descending, and right coronary arteries were measured. The normal ranges for coronary artery (CA) size defined according to the age or body weight were used18). In children younger than 5 years, an internal luminal diameter (ILD) ≤3.0 mm was considered normal, while in children aged 5 years or older, an ILD≤4.0 mm is considered normal. Grouping children by weighing less than 12.5, 12.5–27.5, and more than 27.5 kg, the normal ranges of ILD were defined as ≤2.5, and 2.5–3.0, and 3.0–5.0 mm, respectively. If the ILD of CA segment was enlarged less than 1.5 times of the upper normal limit, it was defined as dilatation, and if the ILD was enlarged 1.5 times or more, it was defined as aneurysm.

5. Statistical analysis

All statistical analyses were performed using IBM SPSS ver. 18.0 (IBM Co., Armonk, NY, USA), and the data were presented as mean±standard deviation or as percentages. Variables were compared between 2 groups using the unpaired Student t test, Pearson chi-square test, and one-way analysis of variance. P values of <0.05 were considered statistically significant. This study was approved by the Institutional Review Board of the School of Medicine of The Catholic University of Korea (UC15RISI0098).

Results

During the study period, 111 patients were diagnosed having IKD at Uijeongbu St. Mary's Hospital. Of these, 41 had AU on admission (group 1), and 70 did not have AU (group 2). The demographic data of each group are summarized in Table 1. The mean age was significantly older in group 1 than in groups 2 (46.5±19.93 months vs. 29.8±21.28 months, P<0.001). This data might mean that there could be some patients with AU in the group 2, because the very young aged patients might not get the correct diagnosis of AU due to the lack of cooperation during slit lamp examination. Males predominated (67 of 111, 60.3%) as like as the patients with complete KD and the male-to-female ratio was 1.5:1. The duration of fever before the first IVIG was not significantly different between the 2 groups (P=0.533). There was no significant difference in the number of diagnostic criteria between 2 groups (Table 2), and all of the enrolled patients had desquamation of finger tips and thrombocytosis in the subacute phase of KD, confirming the final diagnosis of KD. The rates of additional IVIG treatment did not significantly differ between the two groups. The necessity of second-line therapy, such as systemic corticosteroid or infliximab, was significantly higher in group 2 than in group 1. Group 2 had a significantly longer duration of hospitalization than group 1. The laboratory results on admission did not differ significantly between the two groups (Table 3). CA dilatation was observed in 3 patients in group 1 (1.7%), 19 patients in group 2 (27.1%), and the rate of dilatation was significantly higher in group 2 than in group 1 (Table 4) (P=0.008). The only 1 patient in group 2 (1.4%), who received infliximab, developed giant coronary aneurysm. The fact that group 1 had lower risk of CALs than group 2 seemed to demonstrate that the detection of AU could lead to earlier diagnosis and treatment of patients with IKD before they develop CALs (relative risk [RR], 1.298; 95% confidential interval, 10.93–1.540).
Table 1

Demographic data in patients with incomplete Kawasaki disease with and without anterior uveitis

DemographicIKD with AU (n=41)IKD without AU (n=70)P value
Age (mo)46.5±19.929.8±21.3<0.001
Median age (mo)46.027.0<0.001
Male sex18/41 (43.9)49/70 (70.0)0.007
Duration of fever (day)6.1±1.26.4±2.10.533

Values are presented as mean±standard deviation or number (%).

IKD, incomplete Kawasaki disease; AU, anterior uveitis.

Table 2

Diagnostic criteria in incomplete Kawasaki disease patients with and without anterior uveitis

Principal criteriaIKD with AU (n=41)IKD without AU (n=70)P value
Conjunctival injection38 (92)66 (94)0.737
Strawberry tongue27 (65)43 (61)0.641
Cervical LAP, >1.5 cm16 (39)29 (41)0.803
Polymorphous rash27 (65)48 (68)0.768
Hand or foot edema10 (24)10 (14)0.181
Skin desquamation41 (100)70 (100)-

Values are presented as number (%).

IKD, incomplete Kawasaki disease; AU, anterior uveitis; LAP, lymphadenopathy.

Table 3

Laboratory results of patients with incomplete Kawasaki disease with and without anterior uveitis at admission

Blood testsIKD with AU (n=41)IKD without AU (n=70)P value
WBC (/µL)15,416.6±5,419.814,769.3±4,722.00.647
Hb (g/dL)11.7±1.111.4±1.00.078
Hct (%)34.0±2.833.4±2.70.299
Platelets (×103/µL)335.6±80.1367.1±98.50.067
ESR (mm/hr)62.9±25.757.5±26.80.371
CRP (mg/dL)7.1±4.28.7±8.30.160
Albumin (g/dL)3.8±0.43.8±0.30.689
AST (U/L)71.8±81.871.7±100.80.939
ALT (U/L)97.1±134.673.2±102.70.296

Values are presented as mean±standard deviation.

IKD, incomplete Kawasaki disease; AU, anterior uveitis; WBC, white blood cell; Hb, hemoglobin; Hct, hematocrit; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase.

Table 4

Proportion of coronary artery lesion in incomplete Kawasaki disease patients with or without anterior uveitis (n=111)

IKDCAL (+)CAL (–)P value
IKD with AU (n=41)3/41 (7.3)38/41 (92.6)0.008
IKD without AU (n=70)20/70 (28.5)50/70 (71.4)

IKD, incomplete Kawasaki disease; AU, anterior uveitis; CAL, coronary artery lesion.

Relative risk, 1.298; 95% confidential interval, 1.093–1.540.

Discussion

Kawasaki disease is the most common acquired heart disease in children. Delayed treatment can cause cardiac complications, including CA dilatation and aneurysm, myocardial infarction, pericardial effusion, valvular regurgitation. KD is diagnosed using the diagnostic criteria1218) based on the clinical symptoms and laboratory findings, because there is no specific diagnostic test. Ophthalmologic manifestations of KD have been described since 198119), mostly nonexudative bulbar conjunctivitis and uveitis12). Superficial punctate keratitis, vitreous opacity, choroidal and retinal changes, papilledema, subconjunctival hemorrhage, and macular edema are less common20). Some studies have included AU as an additional diagnostic tool that can be helpful for the early recognition and treatment of IKD212223) and the prevention of CALs. The patients with IKD younger than 6 months of age, or older than 5 years of age, have higher possibility of developing CA complications due to late diagnosis and treatment35). Uveitis can be classified anatomically, with AU accounting for 30%–40%, posterior uveitis accounting for 40%–50%, intermediate uveitis accounting for 10%–20%, and diffuse uveitis accounting for 5%–10%24). The most common cause24) of AU in children is juvenile idiopathic arthritis, while other diseases can be associated with AU including KD, retinoblastoma, leukemia, juvenile xanthogranuloma, Coat's disease, retinitis pigmentosa, herpes virus infection, sarcoidosis, and retained intraocular foreign bodies following trauma. CALs were significantly less common in group 1 than group 2 (7.3% vs. 28.5%, P=0.008). Therefore, if a patient has an unexplained persistent fever and IKD is suspected, an ophthalmic examination is needed to identify the presence of AU. Korea has the second highest incidence rate of KD in the world. However, we do not have our own diagnostic criteria for KD and should establish Korean diagnostic guidelines of the disease with additional criteria such as AU for the early diagnosis of IKD and prevention of CA complications. To do this, it is necessary to objectively assess whether the detection of AU can help to diagnose and reduce the occurrence of CALs by preventing treatment delay through the triennial nationwide epidemiological survey in Korea. This study is the first such study in Korea, but it has some limitations. First, all of the patients with KD were not included, and only those with suspected IKD underwent ophthalmologic examinations. Second, the study had a small sample size because it was conducted at a single institute. Finally, the study was not a nationwide prospective study. We are planning a more objective, systematic study on IKD. We recommend that all patients with KD should be consulted to an ophthalmologist to determine the presence of AU. We think that AU may be recognized as one of the essential diagnostic criteria of KD, and the presence of AU may lead to the early diagnosis and treatment of IKD, reducing the occurrence of CALs. In conclusion, we recommend that pediatricians should consider AU as an important finding and cooperate with ophthalmologists when managing patients with suspected IKD.
  23 in total

1.  Coronary artery lesions of incomplete Kawasaki disease: a nationwide survey in Japan.

Authors:  Daisuke Sudo; Yoshiro Monobe; Mayumi Yashiro; Makiko Naka Mieno; Ritei Uehara; Keiji Tsuchiya; Tomoyoshi Sonobe; Yosikazu Nakamura
Journal:  Eur J Pediatr       Date:  2011-12-10       Impact factor: 3.183

2.  BCG reactivation: a useful diagnostic tool even for incomplete Kawasaki disease.

Authors:  R Sinha; T Balakumar
Journal:  Arch Dis Child       Date:  2005-09       Impact factor: 3.791

Review 3.  Ocular manifestations of systemic inflammatory diseases.

Authors:  Amir Mohsenin; John J Huang
Journal:  Conn Med       Date:  2012-10

4.  Increased incidence of incomplete Kawasaki disease at a pediatric hospital after publication of the 2004 American Heart Association guidelines.

Authors:  Sunil J Ghelani; Craig Sable; Bernhard L Wiedermann; Christopher F Spurney
Journal:  Pediatr Cardiol       Date:  2012-02-15       Impact factor: 1.655

5.  Complete and incomplete Kawasaki disease: two sides of the same coin.

Authors:  Cedric Manlhiot; Erin Christie; Brian W McCrindle; Hans Rosenberg; Nita Chahal; Rae S M Yeung
Journal:  Eur J Pediatr       Date:  2011-12-03       Impact factor: 3.183

6.  [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].

Authors:  T Kawasaki
Journal:  Arerugi       Date:  1967-03

7.  Kawasaki's disease in northern Italy: a multicenter retrospective study of 250 patients.

Authors:  F Falcini; R Cimaz; G B Calabri; P Picco; G Martini; M G Marazzi; G Simonini; F Zulian
Journal:  Clin Exp Rheumatol       Date:  2002 May-Jun       Impact factor: 4.473

8.  Follow-up ophthalmologic examinations in children with Kawasaki's disease.

Authors:  M J Burke; R M Rennebohm; W Crowe; J E Levinson
Journal:  Am J Ophthalmol       Date:  1981-04       Impact factor: 5.258

9.  Kawasaki disease patients with redness or crust formation at the Bacille Calmette-Guérin inoculation site.

Authors:  Ritei Uehara; Hiroshi Igarashi; Mayumi Yashiro; Yosikazu Nakamura; Hiroshi Yanagawa
Journal:  Pediatr Infect Dis J       Date:  2010-05       Impact factor: 2.129

10.  Eye involvement in Kawasaki disease.

Authors:  M J Burke; R M Rennebohm
Journal:  J Pediatr Ophthalmol Strabismus       Date:  1981 Sep-Oct       Impact factor: 1.402

View more
  6 in total

1.  Clinical implications in laboratory parameter values in acute Kawasaki disease for early diagnosis and proper treatment.

Authors:  Yu-Mi Seo; Hyun-Mi Kang; Sung-Churl Lee; Jae-Won Yu; Hong-Ryang Kil; Jung-Woo Rhim; Ji-Whan Han; Kyung-Yil Lee
Journal:  Korean J Pediatr       Date:  2018-05-28

2.  Etiological and pathophysiological enigmas of severe coronavirus disease 2019, multisystem inflammatory syndrome in children, and Kawasaki disease.

Authors:  Jung-Woo Rhim; Jin-Han Kang; Kyung-Yil Lee
Journal:  Clin Exp Pediatr       Date:  2021-11-23

3.  LeMeDISCO is a computational method for large-scale prediction & molecular interpretation of disease comorbidity.

Authors:  Courtney Astore; Hongyi Zhou; Bartosz Ilkowski; Jessica Forness; Jeffrey Skolnick
Journal:  Commun Biol       Date:  2022-08-25

4.  Bilateral anterior uveitis as a part of a multisystem inflammatory syndrome secondary to COVID-19 infection.

Authors:  Emmanuel Bettach; David Zadok; Yishay Weill; Kobi Brosh; Joel Hanhart
Journal:  J Med Virol       Date:  2020-09-30       Impact factor: 20.693

Review 5.  Adjuvant herbal therapy for targeting susceptibility genes to Kawasaki disease: An overview of epidemiology, pathogenesis, diagnosis and pharmacological treatment of Kawasaki disease.

Authors:  Bin Tang; Hang Hong Lo; Cheng Lei; Ka In U; Wen-Luan Wendy Hsiao; Xiaoling Guo; Jun Bai; Vincent Kam-Wai Wong; Betty Yuen-Kwan Law
Journal:  Phytomedicine       Date:  2020-03-18       Impact factor: 5.340

6.  Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia.

Authors:  Hun-Ju Yu; Meng-Ni Chuang; Chiao-Lun Chu; Pei-Lin Wu; Shu-Chen Ho; Ho-Chang Kuo
Journal:  J Clin Med       Date:  2021-03-30       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.